Non-GAAP Research and Development expenses for 2011 are expected to be approximately 18 percent of sales, including activities associated with Taligen’s programs.. Alexion announces acquisition of Taligen Therapeutics Alexion Pharmaceuticals, Inc. Announced that it has acquired Taligen Therapeutics, Inc., a held development-stage biotechnology firm located in Cambridge privately, Mass. The acquisition broadens Alexion’s portfolio of product candidates and expands Alexion’s capabilities in translational medication by bringing additional accomplished researchers to the Company.In a scholarly research executed at Wake Forest Baptist INFIRMARY, researchers discovered that African-Americans donate almost to family members for living kidney transplants specifically, in comparison with Caucasians. The retrospective research, published in the September/October online issue of the journal Clinical Transplantation, compared medical records of all former effective kidney donors at Wake Forest Baptist between Jan. 1, 1991, and Dec. 31, 2009. The purpose of the analysis was to characterize distinctions in donor and recipient romantic relationships between African-American and Caucasian living kidney donors.